LivaNova Revenue and Competitors

Location

$17.6M

Total Funding

Estimated Revenue & Valuation

  • LivaNova's estimated annual revenue is currently $1B per year.(i)
  • LivaNova's estimated revenue per employee is $267,602
  • LivaNova's total funding is $17.6M.
  • LivaNova's current valuation is $4.5B. (January 2022)

Employee Data

  • LivaNova has 3849 Employees.(i)
  • LivaNova grew their employee count by 4% last year.

LivaNova's People

NameTitleEmail/Phone
1
Chief StaffReveal Email/Phone
2
Global procurement Vice presidentReveal Email/Phone
3
CEOReveal Email/Phone
4
VP, North America Sales EpilepsyReveal Email/Phone
5
VP, Emerging TherapiesReveal Email/Phone
6
VP Program Management OfficeReveal Email/Phone
7
VP Commercial OperationsReveal Email/Phone
8
VP, Global Sales and MarketingReveal Email/Phone
9
VP (General Manager Level) Sleep Apnea and EpilepsyReveal Email/Phone
10
Head LATAM BusinessReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is LivaNova?

LivaNova is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol ᅢᄁ¬ツᆲᅤモLIVN.ᅢᄁ¬ツᆲᅡン LivaNova is a market leader with a workforce of more than 3,500 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova operates as two businesses: ᅢᄁ¬ツᆲᅡᄁ Cardiac Surgery: We are a global leader in cardiac surgery based on many factors, including our established leadership position in heart-lung machines and recognition as the worldᅢᄁ¬ツᆲ¬トᄁs #1 cardiopulmonary bypass company. Our advanced solutions have made significant contributions to open-heart surgery outcomes for many patients. Notably, we offer the only sutureless valve for aortic surgery. We also offer Advanced Temporary Cardiopulmonary Support Systems, including ExtraCorporeal Life Support and Percutaneous Mechanical Circulatory Support. ᅢᄁ¬ツᆲᅡᄁ Neuromodulation: As pioneers of the VNS (Vagus Nerve Stimulation) Therapyᅢツᅡᆴ System, we continue to advance medical device solutions for people affected by Drug-Resistant Epilepsy, Treatment-Resistant Depression and Heart Failure. We also treat obstructive sleep apnea (OSA) with an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, opening the airway while a patient is sleeping. At LivaNova, we serve health and improve lives. Day by day. Life by life.

keywords:N/A

$17.6M

Total Funding

3849

Number of Employees

$1B

Revenue (est)

4%

Employee Growth %

$4.5B

Valuation

N/A

Accelerator

LivaNova News

2022-04-20 - LivaNova (LIVN) Scheduled to Post Earnings on Wednesday

Analysts expect LivaNova to post earnings of $0.52 per share for the quarter. LivaNova has set its FY22 guidance at $2.50-2.80 EPS and its FY...

2022-04-20 - Epilepsy Market Size, Scope And Outlook | LivaNova Plc ...

LivaNova Plc, GlaxoSmithKline Plc, Novartis AG, Medtronic, Pfizer Inc., Abbott Laboratories. Market factors could use prospect information to...

2022-03-30 - LivaNova Initiates Targeted Commercial Launch of the Essenz ...

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$969.9M38493%N/A
#2
$2510M38503%N/A
#3
$1457.6M38568%N/A
#4
$1565.9M38571%N/A
#5
$1383.6M38917%N/A